STERIS (NYSE:STE) Releases FY 2026 Earnings Guidance

STERIS (NYSE:STE) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 10.150-10.300 for the period, compared to the consensus EPS estimate of 10.220. The company issued revenue guidance of $5.9 billion-$6.0 billion, compared to the consensus revenue estimate of $5.9 billion.

STERIS Price Performance

STERIS stock opened at $243.81 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37. The company has a market cap of $23.93 billion, a P/E ratio of 34.00 and a beta of 1.03. STERIS has a one year low of $204.90 and a one year high of $269.44. The business has a fifty day moving average of $258.70 and a two-hundred day moving average of $249.50.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, meeting analysts’ consensus estimates of $2.53. The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.48 billion. STERIS had a return on equity of 14.49% and a net margin of 12.15%.STERIS’s quarterly revenue was up 9.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.32 EPS. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. As a group, analysts predict that STERIS will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, February 17th. STERIS’s dividend payout ratio (DPR) is currently 36.21%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.20.

Insider Buying and Selling

In other STERIS news, VP Renato Tamaro sold 5,036 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the sale, the vice president directly owned 5,695 shares of the company’s stock, valued at $1,466,747.25. The trade was a 46.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Julia Madsen sold 5,008 shares of STERIS stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $262.00, for a total value of $1,312,096.00. Following the sale, the vice president owned 10,710 shares of the company’s stock, valued at approximately $2,806,020. This represents a 31.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 25,044 shares of company stock worth $6,586,218 in the last three months. 1.07% of the stock is currently owned by insiders.

Institutional Trading of STERIS

A number of large investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. grew its holdings in STERIS by 34.9% in the 2nd quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 45 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of STERIS by 2.4% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 2,261 shares of the medical equipment provider’s stock valued at $560,000 after purchasing an additional 53 shares in the last quarter. Fiduciary Trust Co increased its position in STERIS by 0.9% in the 3rd quarter. Fiduciary Trust Co now owns 6,785 shares of the medical equipment provider’s stock valued at $1,679,000 after buying an additional 61 shares in the last quarter. Quadrant Capital Group LLC raised its holdings in shares of STERIS by 3.2% in the 3rd quarter. Quadrant Capital Group LLC now owns 2,429 shares of the medical equipment provider’s stock worth $601,000 after acquiring an additional 75 shares during the last quarter. Finally, Gallagher Fiduciary Advisors LLC grew its position in STERIS by 5.0% in the 2nd quarter. Gallagher Fiduciary Advisors LLC now owns 2,153 shares of the medical equipment provider’s stock worth $517,000 after purchasing an additional 102 shares in the last quarter. 94.69% of the stock is owned by institutional investors.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.